Market Pulse LIVECAST Terminal Brief Politics Macro Calendar

More

Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Market Pulse LIVECAST

Menu

Home Market Pulse LIVECAST Terminal Brief Politics Macro Calendar Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Live News EQUITY L impact Jul 10, 2026, 11:54 AM UTC

10072026TradeBalanceNO

10072026TradeBalanceNO

SQUAWKNEWS

10072026TradeBalanceNO

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

Shein Likely To Aim For September/October IPO After Getting Chinese Regulatory Approval, -RTRS Cites Source Familiar With The Situation Shein Likely To Aim For September/October IPO After Getting Chinese Regulatory Approval, -RTRS Cites Source Familiar With The Situation L impact | EQUITY | Jul 10, 2026, 12:58 PM UTC FirstSun Capital price target lowered to $44 from $47 at Raymond James Raymond James analyst Michael Rose lowered the firm's price target on FirstSun Capital to $44 from $47 and keeps a Strong Buy rating on the shares. FirstSun Capital shares declined H impact | EQUITY | Jul 10, 2026, 12:52 PM UTC Sanofi announces subcutaneous Sarclisa Escena approved in U.S. The U.S. Food and Drug Administration has approved subcutaneous Sarclisa Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma ac L impact | EQUITY | Jul 10, 2026, 12:43 PM UTC Nurix Therapeutics price target raised to $34 from $32 at Truist Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The company's earnings H impact | EQUITY | Jul 10, 2026, 12:42 PM UTC Voya Financial price target raised to $125 from $95 at UBS UBS raised the firm's price target on Voya Financial to $125 from $95 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q2 earnings report. H impact | EQUITY | Jul 10, 2026, 12:40 PM UTC Clearmind Medicine submits response to HHS request for information Clearmind Medicine announced that it has submitted a formal response to the U.S. Department of Health and Human Services, or HHS, request for information about MEAI's potential as L impact | EQUITY | Jul 10, 2026, 12:36 PM UTC

SQUAWK/NEWS

Real-time financial news agency. Market-moving headlines, macro, politics, filings and audio squawk built for traders.

Product

LiveCast
Terminal
Brief
Macro
Calendar
Search

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact

© 2026 SquawkNews robots / sitemap SquawkNews publishes factual market information and context. It is not investment advice and does not provide trade recommendations.